Neurogene Inc. NGNE
Regular-session close
After hours · Nov 19, 5:15 PM ET
- YTD
- +11.31%
- 1 year
- +9.24%
5D -3.13 (-11.93%)
- Market cap
- 474.67M
- Revenue (ttm)
- 925.00K
- EPS (ttm)
- -5.03
- Shares out
- 14.85M
- Forward P/E
- -4.85
- YTD return
- +11.31%
- 1-year return
- +9.24%
- 50-day average
- 37.48
- Volume
- 149.84K
- Avg volume
- 309.99K
- Open
- 23.22
- Previous close
- 23.14
- Day's range
- 22.52 – 23.36
- 52-week range
- 15.93 – 43.66
- Analysts
- Strong Buy
- Price target
- 52.80 (+130.3%)
Key statistics
- 200-day average
- 37.96
- Enterprise value
- 117.41M
- Price / sales
- 361.33
- Price / book
- 1.55
- Free cash flow
- -34.07M
- Total cash
- 153.90M
- Total debt
- 13.79M
- Return on equity
- -41.34%
- Short % of float
- 7.87%
Fundamental scorecard
3 of 25 checks passed on NGNE’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 18, 2024 | Sep 1, 2024 | -1.23 | -1.19 | +0.04 | +3.25% |
| Aug 9, 2024 | Jun 1, 2024 | -1.02 | -1.09 | -0.07 | -6.86% |
| May 10, 2024 | Mar 1, 2024 | -1.03 | -1.00 | +0.03 | +2.91% |
| Apr 2, 2024 | Dec 1, 2023 | -1.30 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 20, 2024 | BMO Capital | main | Outperform | Outperform |
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | Stifel | main | Buy | Buy |
| Nov 12, 2024 | BMO Capital | main | Outperform | Outperform |
| Nov 12, 2024 | Leerink Partners | main | Outperform | Outperform |
About Neurogene Inc.
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- neurogene.com
News
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $60
Neurogene Q3 EPS $(1.05) Beats $(1.36) Estimate
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $65 Price Target
Neurogene To Present Data Related To NGN-401 Gene Therapy Program For Rett Syndrome At ESGCT 33rd Annual Congress; New Preclinical Data Expected To Further Validate NGN-401’s Differentiated Design
Your note
Sign in to keep a note on NGNE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 4, 2023 | 0 |
| COBB STUART | Officer | Stock Award(Grant) | Mar 12, 2024 | 20,391 |
| CVIJIC CHRISTINE MIKAIL | President | Purchase | Nov 21, 2024 | 76,844 |
| MCMINN RACHEL L. PH.D. | Chief Executive Officer | Purchase | Nov 21, 2024 | 1,297,860 |
| PATEL PRITI | Former | Sale | Apr 2, 2023 | 37,313 |
| SAMSARA BIOCAPITAL GP, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 25, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.24% | 1,371,879 | 30.87M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 8.56% | 1,271,342 | 28.61M | Sep 29, 2024 |
| Samsara BioCapital, LLC | 8.53% | 1,267,790 | 28.53M | Sep 29, 2024 |
| RTW Investments LP | 7.64% | 1,135,256 | 25.54M | Sep 29, 2024 |
| Great Point Partners LLC | 6.76% | 1,004,291 | 22.60M | Sep 29, 2024 |
| Redmile Group, LLC | 6.49% | 964,347 | 21.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.26% | 335,977 | 7.56M | Sep 29, 2024 |
| BlackRock Health Sciences Term Trust | 2.20% | 326,877 | 7.35M | Sep 29, 2024 |
| Fidelity Small Cap Growth Fund | 1.94% | 288,922 | 6.50M | Aug 30, 2024 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 1.91% | 284,041 | 6.39M | Aug 30, 2024 |
| Janus Henderson Global Life Sciences Fund | 1.87% | 278,165 | 6.26M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.79% | 265,755 | 5.98M | Oct 30, 2024 |
